Jazz Pharmaceuticals (JAZZ) PT Lowered to $129 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $215.98 --0%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Join SI Premium – FREE
Piper Sandler analyst David Amsellem lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $129.00 (from $142.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Methanex (MEOH) PT Raised to $63 at JPMorgan Amid Higher Methanol Prices
- Pampa Energia S.A. (PAM) PT Lowered to $100 at JPMorgan
- Intrepid Potash (IPI) PT Lowered to $41 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
